JenaValve's Response to Recent FTC Action
Recently, JenaValve Technology expressed its disagreement with the U.S. Federal Trade Commission's (FTC) decision to block its planned acquisition by Edwards Lifesciences. The company remains committed to advancing this acquisition, driven by its strong belief in the mutual benefits it offers to patients suffering from aortic regurgitation.
Commitment to Patient Care
Despite the FTC's decision, JenaValve is determined to proceed with its plans. The company believes that the acquisition possesses the potential to significantly enhance treatment options for patients dealing with heart valve diseases. Their confidence stems from a distinct rationale supporting this transaction, which they argue will provide crucial benefits to many individuals affected by severe aortic regurgitation.
Legal Avenues and Future Plans
In light of the FTC's challenge, JenaValve has opted to collaborate with Edwards Lifesciences in a legal defense to pursue the acquisition. This partnership is anticipated to better articulate the value of the merger and the innovations that will arise from their combined expertise.
Introduction to JenaValve
At its core, JenaValve Technology, Inc. is a pioneering medical device firm dedicated to the design, development, and commercialization of transformative transcatheter heart valve (THV) solutions. The trilogy THV system, one of its flagship products, is engineered to treat patients suffering from symptomatic, severe aortic regurgitation (AR) and aortic stenosis who are at elevated surgical risk. Having achieved CE Mark approval, the Trilogy THV system stands as a testament to JenaValve's innovation, representing the first TAVR device offering true dual-disease treatment capabilities.
Global Presence and Innovation
JenaValve is headquartered in Irvine, California, with additional facilities located in Leeds, United Kingdom, and Munich, Germany. This international presence underscores the company's commitment to global health solutions aimed at improving patient outcomes through innovative technologies.
Partnerships and Backing
To fuel its growth and innovation, JenaValve enjoys robust support from a variety of investment partners, including Bain Capital Life Sciences, Andera Partners, Valiance Life Sciences, and several other private equity firms. These partnerships not only provide the necessary capital but also valuable expertise to navigate the expanding landscape of heart valve therapy.
Research and Development Focus
JenaValve which is currently limited to investigational use in the U.S. is committed to furthering its research and developing products that address the pressing needs of patients with heart valve diseases. The focus on innovative therapies is central to the company’s mission of providing safer and more effective treatment options.
Frequently Asked Questions
What is JenaValve's main product?
JenaValve's primary innovation is the Trilogy THV System designed for patients with severe heart valve diseases.
What was the FTC's action regarding JenaValve?
The FTC moved to block JenaValve's proposed acquisition by Edwards Lifesciences, prompting a legal response from JenaValve.
Why is JenaValve pursuing this acquisition?
JenaValve believes the acquisition will enhance treatment opportunities for patients suffering from aortic regurgitation.
Where is JenaValve located?
JenaValve is headquartered in Irvine, California, with facilities in the UK and Germany.
What is the focus of JenaValve's research?
The company focuses on developing innovative heart valve therapies and solutions for enhanced patient care.
